

INNOVA CAPTAB LIMITED
Plot No. 320, Industrial Area, Phase-1,
Panchkula, Pin-134113, Haryana, India.
Phone: +91-172-4194500



07th May, 2026

To,
BSE Limited
Phiroze Jeejeebhoy Towers,
Dalal Street, Mumbai – 400001
BSE Symbol: INNOVACAP
BSE Scrip Code: 544067

To,
National Stock Exchange of India Limited
Exchange Plaza, C-1, Block G,
Bandra Kurla Complex
Bandra (E), Mumbai – 400051
NSE Symbol: INNOVACAP

Dear Sir/Madam,

Subject: Intimation of Investor Presentation for the Analysts/ Institutional Investor Meeting to be held for Financial Results of quarter and financial year ended 31st March, 2026

This is in continuation to our intimation dated 30th April, 2026 wherein we had informed regarding an Earnings Call scheduled with Analysts / Investors on Friday, 08th May, 2026 at 11:00 A.M. (IST) to discuss the Audited Financial Results for the quarter and financial year ended 31st March, 2026.

Pursuant to regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, please find enclosed herewith the Investor Presentation for the said Earnings Call.

This is for your information and record.

Thanking you,

Yours faithfully,
For Innova Captab Limited

Neeharika Shukla
Company Secretary and Compliance Officer

Encl.: A/a

A large, 3D-rendered DNA double helix is the central focus, with blue and red strands. The background is a light blue gradient with various molecular models, including ball-and-stick structures, hexagonal rings, and a blue-and-white capsule, all rendered in a semi-transparent, glowing style.


Excelling with Passion Powering Potential

Investor Presentation - May 2026


This presentation and the accompanying slides (the “Presentation”), which have been prepared by **Innova Captab Limited (the “Company”)**, have been prepared solely for information purposes and do not constitute any offer, recommendation or invitation to purchase or subscribe for any securities, and shall not form the basis or be relied on in connection with any contract or binding commitment whatsoever. No offering of securities of the Company will be made except by means of a statutory offering document containing detailed information about the Company.

This Presentation has been prepared by the Company based on information and data which the Company considers reliable, but the Company makes no representation or warranty, express or implied, whatsoever, and no reliance shall be placed on, the truth, accuracy, completeness, fairness and reasonableness of the contents of this Presentation. This Presentation may not be all inclusive and may not contain all of the information that you may consider material. Any liability in respect of the contents of, or any omission from, this Presentation is expressly excluded.

This presentation contains certain forward-looking statements concerning the Company’s future business prospects and business profitability, which are subject to a number of risks and uncertainties and the actual results could materially differ from those in such forward-looking statements. The risks and uncertainties relating to these statements include, but are not limited to, risks and uncertainties regarding fluctuations in earnings, our ability to manage growth, competition (both domestic and international), economic growth in India and abroad, ability to attract and retain highly skilled professionals, time and cost over runs on contracts, our ability to manage our international operations, government policies and actions regulations, interest and other fiscal costs generally prevailing in the economy. The Company does not undertake to make any announcement in case any of these forward-looking statements become materially incorrect in future or update any forward-looking statements made from time to time by or on behalf of the Company.



Company Overview



Leading Pharmaceutical Player with Comprehensive Business Model

Preferred CDMO partner for prominent pharmaceutical companies worldwide, with a strong direct presence across geographies through our branded generics business



350 +
CDMO Customers across
the Globe



Presence across **60+**
countries



Comprehensive portfolio
of **4,200+** products



Serving some
of the **prominent**
Pharmaceutical companies
globally



Strong network of
2,50,000+
touchpoints in India

Robust Financials
(FY26)

Revenues
₹ **1,630 Cr**

EBITDA
₹ **250 Cr**
(15.4%)

PAT
₹ **141 Cr**
(8.6%)

ROCE
14.5%

Journey of Achieving Major Milestones

- Innova Captab began its journey in 2006 with the establishment of first manufacturing plant in Baddi, Himachal Pradesh

Foundation 2006

- Received GMP Certificate for cephalosporin products from the Ministry of Medical Services, Republic of Kenya

International GMP Certification 2013

- Further expanded the G block to achieve its current capacity levels

Further Expansion 2018-21

- **Acquisition of Sharon**
Acquisition of Sharon, through the Corporate Insolvency Resolution Process (CIRP) process.

- **Initial Public Offer (IPO)**
Successfully got listed on stock exchanges in December 2023.

2023-24

2010 Establishment of Cephalosporin plant

- Established and commenced operations at the Cephalosporin block in Baddi

2015-17 Establishment of Marketing Arm

- Incorporated Univentis Medicare Limited through which the marketing operations are undertaken

- **Establishment of G Block**
Commenced operations at newly established G Block in Baddi plant.


2022 Strategic Expansion

- Commenced construction to establish a manufacturing plant in Jammu and Kashmir and to build an R&D center in Panchkula, Haryana.

2025-26 Commercialization of Jammu Plant

- Commenced commercial operations at our state-of-the-art manufacturing facility in Kathua, Jammu in January 2025
- **Certification of GMP Compliance**
 - Received Certificate of GMP Compliance by UK-MHRA for Cephalosporin, Baddi facility
 - Received Certificate of GMP Compliance from PIC/s (SMDC, Ukraine) for Kathua, Jammu facility

With State-of-the-Art Manufacturing Facilities



9
Manufacturing Blocks
3 Baddi | 1 Dehradun | 1 Taloja | 4 Jammu

New Greenfield
Multipurpose Facility
(4 manufacturing blocks) in Kathua, Jammu commercialized in Jan'25

Third Largest
Finished Tablet and Capsule
Manufacturing Capacity in India¹

High FATR
Track record of operating at high
Fixed Asset Turnover Ratio

Key Accreditations



¹ Crisil Report, October 2023

Disclaimer: This map is a generalized illustration only for the ease of the reader to understand the locations, and it is not intended to be used for reference purposes. The representation of political boundaries and the names of geographical features/states do not necessarily reflect the actual position. Our Company or any of our Directors, officers or employees cannot be held responsible for any misuse or misinterpretation of any information or design thereof. Our Company does not warrant or represent any kind of connection with its accuracy or completeness.



Q4 & FY26
Performance Highlights



Innova Captab Ltd. has a strong performance with YoY revenue growth of 42% in Q4 FY26 and has delivered its highest-ever annual revenue with a growth of 31% in FY26. This strong performance underscores disciplined execution across our operations.

This milestone performance was driven by sustained momentum across our CDMO and branded generics businesses, supported by an expanding product portfolio and increasing customer engagement.

Operational excellence remains central, backed by state-of-the-art manufacturing infrastructure and stringent quality processes. During the year, we received key certifications including UK-MHRA for our Baddi facility and PIC/S for our Jammu blocks, enhancing our presence in regulated markets.


The Jammu facility has completed its first full year of operations and is ramping up well, with multiple marquee clients successfully completing regulatory and customer audits.

With multiple growth levers in place, we remain confident in sustaining momentum and delivering long-term value to our stakeholders.




Q4 & FY26 Performance Highlights - Revenue

Revenue (₹ Crore)



Business Areas (₹ Crore)



- Revenue from Operations registered strong YoY growth of 42% in Q4 and 31% in FY26
 - This performance was driven by strong momentum across both business areas.
 - Exports contributed 28% to the overall revenue mix in Q4 FY26 and 31% in FY26
- CDMO operations delivered strong YoY growth of 41% in Q4 FY26 and 24% in FY26
 - Growth was led by increased product portfolio, adding new customers and deepening wallet share with existing customers
- Branded Generics business reported robust YoY growth of 46% in Q4 FY26 and 51% in FY26
 - This growth clearly showcases a pure testament to our distribution strategies, both in India and internationally

Q4 & FY26 Performance Highlights - Profitability

EBITDA (₹ crore)


Margin

16.2%

14.9%

15.9%

15.4%



PAT (₹ crore)


Margin

9.4%

8.5%

10.3%

8.6%



- EBITDA for Q4 FY26 stood at ₹ 66.7 crores reflecting a robust YoY growth of 31%. For FY26, EBITDA was ₹ 250.3 crores, up 26% YoY.
- EBITDA margin came in at 14.9% in Q4 FY26 and 15.4% in FY26
- Profit after Tax was ₹ 38.1 crores in Q4 FY26 recording strong YoY growth of 29% and was ₹ 140.9 crores in FY26 with a YoY growth of 10%
- PAT margin was 8.5% for Q4 FY26 and 8.6% for FY26

Consolidated Profit & Loss Statement


Profit and Loss (₹ crore)	Q4 FY26	Q4 FY25	YoY Growth	FY26	FY25	YoY Growth
Revenue from Operations	447.8	314.7		1,630.0	1,243.7	
Other Income	1.6	3.4		7.4	12.0	
Total Income	449.4	318.1	41.3%	1,637.4	1,255.7	30.4%
Cost of Material Consumed	296.7	198.0		1,052.8	814.1	
Employee Cost	42.6	35.5		167.2	116.8	
Other Expenses	43.4	33.5		167.1	126.6	
EBITDA	66.7	51.1	30.5%	250.3	198.2	26.3%
EBITDA Margin	14.9%	16.2%		15.4%	15.9%	
Depreciation	11.4	9.8		45.2	24.8	
Finance Cost	4.6	2.0		16.9	2.4	
Profit before Tax	50.7	39.3		188.3	171.0	
Tax	12.6	9.7		47.3	42.8	
Profit After Tax	38.1	29.6	28.8%	140.9	128.3	9.9%
Profit After Tax Margin	8.5%	9.4%		8.6%	10.3%	
EPS (in ₹)	6.65	5.17		24.63	22.41	

Consolidated Balance Sheet


Assets (₹ crore)	Mar 2026	Mar 2025	Equity & Liabilities (₹ crore)	Mar 2026	Mar 2025
Non - Current Assets	914.4	877.3	Total Equity	1,090.8	959.4
Property, plant and equipment	779.7	766.9	Share Capital	57.2	57.2
Right of use assets	43.7	45.5	Other Equity	1,033.6	902.2
Capital work-in-progress	15.5	22.5	Non-Current Liabilities	252.0	268.0
Goodwill	16.7	16.7	Financial Liabilities		
Other intangible assets	1.5	0.7	Borrowings	214.8	243.5
Financial Assets			Lease liabilities	1.0	1.3
Loans	0.4	0.7	Provisions	11.9	9.9
Other financial assets	41.6	8.3	Deferred tax liabilities (net)	24.3	13.2
Deferred tax assets (net)	1.4	12.2	Other non-current liabilities	0.0	0.0
Income tax assets (net)	0.0	0.2	Current Liabilities	494.6	352.9
Other non-current assets	14.0	3.5	Financial Liabilities		
Current Assets	923.0	703.1	Borrowings	127.9	92.5
Inventories	283.3	208.0	Lease liabilities	0.0	0.7
Financial Assets			Trade payables	318.6	201.8
Investments	41.3	-	Other financial liabilities	28.0	31.8
Trade receivables	437.3	331.6	Other current liabilities	12.6	17.9
Cash and cash equivalents	3.2	15.5	Provisions	4.0	4.2
Other bank balances	0.7	52.6	Current tax liabilities (net)	3.5	4.0
Loans	0.4	0.7	Total Equity & Liabilities	1,837.4	1,580.4
Other financial assets	86.9	32.1			
Other current assets	69.9	55.1			
Assets held for sale	0.0	7.4			
Total Assets	1,837.4	1,580.4			

Consolidated Cash Flow


Particulars (₹ crore)	Mar 2026	Mar 2025
Net Profit Before Tax	188.3	171.0
Adjustments for: Non -Cash Items / Other Investment or Financial Items	57.6	27.4
Operating profit before working capital changes	245.9	198.4
Changes in working capital	(103.1)	(110.8)
Cash generated from Operations	142.8	87.6
Direct taxes paid (net of refund)	(26.2)	(23.7)
Net Cash from Operating Activities	116.5	63.8
Net Cash from Investing Activities	(107.1)	(151.6)
Net Cash from Financing Activities	(21.7)	91.5
Net Decrease in Cash and Cash equivalents	(12.3)	3.8
Add: Cash & Cash equivalents at the beginning of the year	15.5	11.7
Cash & Cash equivalents at the end of the period	3.2	15.5



Key Strengths




Building on Core Strengths, Unlocking Future Growth



Relentless Expansion of Manufacturing Capabilities: Fuel for Sustained Growth (1/3)

Our manufacturing Capabilities



*BFS: Blow Fill Seal


Capacity Expansion in Jammu (2/3)

₹ 480+ crore
Total Capital Investment

Eligible for following benefits via Central Government's 'New Central Sector Scheme

GST-linked incentive totaling to 300% of investment made in eligible plant and machinery available for 10 years

Capital Interest Subvention of 6% per annum on loan against eligible capex



4 Independent Blocks

Cephalosporin

Penem


Penicillin

General




Growth led by Capacity Expansion (3/3)

Baddi Plant




- Expect current capacity to suffice the ongoing demand and increase the overall capacity utilization in upcoming years

Dehradun & Taloja Plant



- Sharon's manufacturing units are nearing optimal utilization, reflecting strong demand and efficient operations
- Aim to create long term synergy with additional product offerings in Formulation & API

Jammu Plant



- Jammu facility has completed its first full year and is ramping up well, with multiple marquee client audits successfully completed

CDMO Services and Products

- Preferred partner for companies seeking to efficiently deliver high-quality, affordable medicines to market.
- Consistently deliver high-quality solutions at scale, while maintaining the flexibility to tailor offerings to the distinct requirements of each partner
- Wide range of dosage forms, including oral solids, oral liquids, dry syrups, dry powder injectables, parenteral and ointments

Branded Generics

- Company's domestic and international branded generics business has a broad reach, enabling it to address a wide spectrum of healthcare needs by effectively delivering high-quality formulations across the world



4,200 +
Products

350 +
CDMO Customers

2,50,000 +
Touchpoints in India

60 +
Exported Countries

Extensive Product Offerings, Wider Reach, Stronger Future



60+
Scientist & Engineers

R&D Laboratory
Baddi, Himachal Pradesh

Robust Research and Development

- Dedicated R&D facility and pilot equipment located in Baddi, Himachal Pradesh, recognized by the DSIR for its in-house R&D work
- State-of-the-art facility equipped with a comprehensive suite of necessary tools for developing solid oral and liquid dosage forms, including RMG/FBP, compression machines, and auto coaters
- Analytical lab is equipped with advanced instruments such as HPLC, UV dissolution apparatuses, Karl Fischer moisture analyzers, sonicators, disintegration testers, thermal stability units, and fume hoods
- Developed Products in Category of Immediate Release, Super Bioavailability Capsules, Nano Size Formulation for Increased Bioavailability, Modified and Sustained Releases and Tablets in Capsules



Experienced Promoters and Board of Directors



Mr. Manoj Kumar Lohariwala
Chairman and Whole-Time Director



Mr. Vinay Lohariwala
Managing Director



Mr. Jayant Vasudeo Rao
Whole-Time Director



Mr. Archit Aggarwal
Non-Executive Non-Independent Director



Mr. Sudhir Kumar Bassi
Non-Executive Independent Director



Ms. Priyanka Dixit Sibal
Non-Executive Independent Director




Mr. Mahendar Korthiwada
Non-Executive Independent Director




Mr. Shirish Gundopant Belapure
Non-Executive Independent Director

Consistent Financial Performance


Revenue from Operations (₹ crore)




EBITDA (₹ crore)




PAT (₹ crore)




ROE/ROCE (%)*



Fixed Asset Turnover (FATR)*



Net Working Capital Days¹




Note: Please refer the Prospectus for formulas

*ROCE/ROE and Fixed Asset Turnover ratio impacted by additional investment in Jammu plant and higher capital base due to IPO in Dec'23

¹ Net Working Capital impacted by increased inventory pertaining to Jammu plant



Historical Financial Performance



Consolidated Profit & Loss Statement

Profit and Loss (₹ crore)	FY26	FY25	FY24	FY23	FY22
Revenue from Operations	1,630.0	1,243.7	1,081.3	926.4	800.5
Other Income	7.4	12.0	12.5	9.2	2.9
Total Revenue	1,637.4	1,255.7	1,093.8	935.6	803.4
Cost of Materials Consumed	1,052.8	814.1	728.3	691.6	617.9
Employee Cost	167.2	116.8	90.7	54.8	40.5
Other Expenses	167.1	126.6	107.8	66.4	46.1
EBITDA	250.3	198.2	166.9	122.8	98.9
EBITDA Margin (%)	15.4%	15.9%	15.4%	13.3%	12.4%
Depreciation	45.2	24.8	16.0	11.1	7.5
Finance Cost	16.9	2.4	21.5	20.0	5.7
Profit before Tax	188.3	171.0	129.5	91.8	85.7
Tax	47.3	42.8	35.2	23.8	21.8
Profit After Tax	140.9	128.3	94.3	68.0	64.0
PAT Margin (%)	8.6%	10.3%	8.7%	7.3%	8.0%
EPS (in ₹)	24.63	22.41	18.66	14.16	13.32

Consolidated Balance Sheet


Assets (₹ crore)	FY26	FY25	FY24	FY23	FY22
Non - Current Assets	914.4	877.3	741.1	261.9	196.4
Property, plant and equipment	779.7	766.9	291.6	150.1	156.6
Right of use assets	43.7	45.5	48.7	15.3	9.3
Capital work-in-progress	15.5	22.5	340.8	21.5	-
Goodwill	16.7	16.7	16.7	16.7	16.7
Other intangible assets	1.5	0.7	0.9	0.8	0.5
Financial Assets					
Loans	0.4	0.7	0.7	0.5	0.2
Other financial assets	41.6	8.3	2.6	0.6	0.8
Deferred tax assets (net)	1.4	12.2	20.0	0.1	0.2
Income tax assets (net)	0.0	0.2	0.0	0.7	4.0
Other non-current assets	14.0	3.5	19.2	55.6	8.1
Current Assets	923.0	703.1	579.8	442.5	379.1
Inventories	283.3	208.0	144.0	117.3	128.4
Financial Assets					
Investments	41.3	-	-	-	-
Trade receivables	437.3	331.6	288.5	265.2	212.7
Cash and cash equivalents	3.2	15.5	11.7	3.5	0.2
Other bank balances	0.7	52.6	75.0	15.4	2.3
Loans	0.4	0.7	0.4	1.0	0.3
Other financial assets	86.9	32.1	7.6	7.2	4.3
Other current assets	69.9	55.1	52.4	32.9	30.9
Assets held for sale	0.0	7.4	0.0	-	-
Total Assets	1,837.4	1,580.4	1,320.9	704.4	575.5
Return on Net Worth	13.82%	14.44%	12.42%	24.58%	30.66%

Equity & Liabilities (₹ crore)	FY26	FY25	FY24	FY23	FY22
Total Equity	1,090.8	959.4	830.9	276.5	208.6
Share Capital	57.2	57.2	57.2	48.0	12.0
Other Equity	1,033.6	902.2	773.7	228.5	196.6
Non-Current Liabilities	252.0	268.0	224.5	150.4	72.4
Financial Liabilities					
Borrowings	214.8	243.5	208.2	134.2	67.4
Lease liabilities	1.0	1.3	2.3	1.4	0.6
Other financial liabilities	-	-	-	7.9	-
Provisions	11.9	9.9	9.1	2.9	2.3
Deferred tax liabilities (net)	24.3	13.2	4.8	3.9	2.1
Other non-current liabilities	-	-	-	0.1	0.1
Current Liabilities	494.6	352.9	265.5	277.6	294.5
Financial Liabilities					
Borrowings	127.9	92.5	33.6	101.0	130.8
Lease liabilities	0.0	0.7	1.0	0.4	0.4
Trade payables	318.6	201.8	179.7	158.5	144.8
Other financial liabilities	28.0	31.8	29.6	11.5	9.3
Other current liabilities	12.6	17.9	17.7	5.6	7.8
Provisions	4.0	4.2	3.1	0.6	0.4
Current tax liabilities (net)	3.5	4.0	0.9	-	1.0
Total Equity & Liabilities	1,837.4	1,580.4	1,320.9	704.4	575.5
Debt/Equity Ratio	0.31	0.35	0.29	0.85	0.95

Consolidated Cash Flow

Particulars (₹ crore)	FY26	FY25	FY24	FY23	FY22
Net Profit Before Tax	188.3	171.0	129.5	91.8	85.7
Adjustments for: Non -Cash Items / Other Investment or Financial Items	57.6	27.4	37.2	25.9	15.3
Operating profit before working capital changes	245.9	198.4	166.7	117.7	101.0
Changes in working capital	(103.1)	(110.8)	7.3	(31.1)	(21.3)
Cash generated from Operations	142.8	87.6	174.0	86.7	79.7
Direct taxes paid (net of refund)	(26.2)	(23.7)	(27.7)	(19.5)	20.8
Net Cash from Operating Activities	116.5	63.8	146.4	67.1	58.9
Net Cash from Investing Activities	(107.1)	(151.6)	(499.0)	(90.8)	(188.3)
Net Cash from Financing Activities	(21.7)	91.5	360.7	27.1	124.8
Net Increase/ (Decrease) in Cash and Cash equivalents	(12.3)	3.8	8.2	3.4	(4.8)
Add: Cash & Cash equivalents at the beginning of the year	15.5	11.7	3.5	0.2	5.0
Cash & Cash equivalents at the end of the period	3.2	15.5	11.7	3.5	0.2

Thank You!



Innova Captab Limited :



Innova Captab Ltd.

CIN – L24246MH2005PLC150371

Mr. Lokesh Bhasin

Email – investors@innovacaptab.com

www.innovacaptab.com

Investor Relations Advisor :

SGA Strategic Growth Advisors

Strategic Growth Advisors Pvt. Ltd.

CIN - U74140MH2010PTC204285

Ms. Shaily Patwa / Mr. Shrikant Sangani

Email – shaily.p@sgapl.net / shrikant.sangani@sgapl.net

Mobile No – 9819494608 / 9619595686

www.sgapl.net